PHAR
Pharming GroupPHAR
PHAR
About: Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
Employees: 382
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
39% more capital invested
Capital invested by funds: $369K [Q3] → $514K (+$145K) [Q4]
20% more funds holding
Funds holding: 5 [Q3] → 6 (+1) [Q4]
0% more ownership
Funds ownership: 0.01% [Q3] → 0.01% (+0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
58%
upside
Avg. target
$26
188%
upside
High target
$37
318%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 93 / 411 met price target | 318%upside $37 | Buy Reiterated | 17 Dec 2024 |
Jefferies Lucy Codrington 100% 1-year accuracy 1 / 1 met price target | 58%upside $14 | Buy Initiated | 9 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website ( www.raredisease-offer.com ). Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release .
Neutral
GlobeNewsWire
1 month ago
Pharming Group to convene Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company's website under Investors/Shareholder Meetings.
Neutral
GlobeNewsWire
1 month ago
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.
Positive
Benzinga
2 months ago
European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug
On Wednesday, Pharming Group N.V. PHAR revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
Neutral
Seeking Alpha
3 months ago
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Sushila Hernandez - Kempen Joe Pantginis - H.C.
Neutral
GlobeNewsWire
4 months ago
Pharming Group to report third quarter 2024 financial results on October 24
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024.
Neutral
GlobeNewsWire
4 months ago
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes
Neutral
GlobeNewsWire
4 months ago
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Neutral
GlobeNewsWire
5 months ago
Pharming Group to participate in September investor conferences
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September:
Neutral
Seeking Alpha
6 months ago
Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript
Pharming Group NV (NASDAQ:PHAR ) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET Company Participants Sijmen de Vries - CEO & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Sushila Hernandez - Van Lanschot Kempen Jeff Jones - Oppenheimer Alistair Campbell - RBC Capital Markets Simon Scholes - First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen; I'm here. Next slide, please.
Charts implemented using Lightweight Charts™